No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
“The addition to yet another set of important clinical guidelines highlights the value BRILINTA can bring to patients with ACS and health care professionals trying to reduce the rate of thrombotic cardiovascular events and the momentum this important treatment option is gaining just four months after FDA approval.”
Levine et al. (2011) studied this question.